Published online October 31, 2008
PEDIATRICS Vol. 122 No. 5 November 2008, pp. 1159 (doi:10.1542/peds.2008-2637)

This Article Extract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Healy, C. M. Articles by Baker, C. J. Search for Related Content PubMed Articles by Healy, C. M. Articles by Baker, C. J. Related Collections Infectious Disease & Immunity Social Bookmarking                         What's this?

LETTER TO THE EDITOR

Fluconazole Prophylaxis Decreases the Combined Outcome of Invasive Candida Infections or Mortality in Preterm Infants: In Reply

C. Mary Healy, MD
Department of Pediatrics,
Baylor College of Medicine,
Houston, TX 77030,
Woman's Hospital of Texas,
Houston, TX 77054

Carol J. Baker, MD
Departments of Pediatrics and Molecular Virology and Microbiology,
Baylor College of Medicine,
Houston, TX 77030,
Woman's Hospital of Texas,
Houston, TX 77054

We thank Dr Kaufman for his comments regarding the safety and efficacy of fluconazole prophylaxis in preventing invasive Candida infections in infants weighing <1000 g at birth. We concur that the evidence from published, randomized, controlled trials (both single and multicenter) strongly supports this approach as a means to prevent Candida-associated death or neurodevelopmental impairment that occurs in almost three quarters of Candida-infected preterm infants.¹ In addition, while being cognizant of the limitation of their retrospective study design, 7 single-center cohort studies with retrospective controls have all demonstrated a reduction in Candida infections and associated deaths through the use of fluconazole prophylaxis. No randomized, controlled trial or retrospective cohort study has reported any fluconazole-attributable adverse events that persisted past hospital discharge. In addition, although justifiable concern for the emergence of fluconazole-resistant Candida species in the NICU has been voiced, this has not been demonstrated to date.^2–4

The majority of infants given fluconazole prophylaxis in all studies reported to date used birth weights of <1000 g as an inclusion criterion.² We agree that rates of invasive Candida infections are considerably higher in infants weighing <750 g and that these infants also are at highest risk of poor outcome. However, the risks of invasive Candida infections in infants with birth weights between 750 and 1000 g are not trivial, and these infants also are likely to have ongoing risk factors that enhance their risk of acquiring infection beyond several weeks of life.¹

Undoubtedly, there are unanswered questions regarding which preterm infants will benefit most from fluconazole prophylaxis. There are approaches that deserve further study, such as targeting infants with different birth weights and gestation, confining prophylaxis to time periods of highest risk, or, conversely, prolonging prophylaxis for infants with ongoing risk factors. Although we agree that such studies are needed, we believe that there are sufficiently strong data to consider fluconazole prophylaxis for infants weighing <1000 g in NICUs in which incidence exceeds 5% and adherence to infection control measures is high.

REFERENCES

1. Benjamin DK Jr, Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006;117 (1):84 –92[Abstract/Free Full Text]
2. Kaufman DA. Fluconazole prophylaxis: can we eliminate invasive Candida infections in the neonatal ICU? Curr Opin Pediatr. 2008;20 (3):332 –340[CrossRef][Web of Science][Medline]
3. Healy CM, Campbell JR, Zaccaria E, Baker CJ. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics. 2008;121 (4):703 –710[Abstract/Free Full Text]
4. Manzoni P, Leonessa M, Galletto P, et al. Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant Candida subspecies. Pediatr Infect Dis J. 2008;27 (8):731 –737[Web of Science][Medline]

---

PEDIATRICS (ISSN 1098-4275). ©2008 by the American Academy of Pediatrics

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. Navidi, J. Chaudhuri, and A. Merewood Accuracy of Breastfeeding Data on the Massachusetts Birth Certificate J Hum Lact, May 1, 2009; 25(2): 151 - 156. [Abstract] [PDF]

This Article Extract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Healy, C. M. Articles by Baker, C. J. Search for Related Content PubMed Articles by Healy, C. M. Articles by Baker, C. J. Related Collections Infectious Disease & Immunity Social Bookmarking                         What's this?